|Bid||32.920 x 1200|
|Ask||32.930 x 4000|
|Day's range||32.220 - 33.030|
|52-week range||24.540 - 37.300|
|PE ratio (TTM)||406.48|
|Earnings date||25 Jul 2018 - 30 Jul 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||33.07|
Let’s talk about the popular Boston Scientific Corporation (NYSE:BSX). The company’s shares saw a significant share price rise of over 20% in the past couple of months on the NYSE.Read More...
After considering various parameters and fundamentals, we help you make a choice between Boston Scientific (BSX) and Baxter (BAX).
Zacks.com featured highlights include: General Motors, Boston Scientific, Antero NRG, AMC and Celanese
ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.
Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical
Boston Scientific’s (BSX) enterprise value is $45.1 billion, and its enterprise-value-to-revenue ratio is 4.98x. The stock is trading at a forward PE multiple of 21.86x, which is expected to have a five-year growth multiple of 2.13x. Its price-to-sales ratio is 5.23x, and its price-to-book ratio is 6.72x. Its enterprise-value-to-EBITDA ratio is 18.5x.
In the first quarter of 2018, Boston Scientific (BSX) generated $193 million from operating activities compared to $7 million in Q1 2017. Boston Scientific used $173 million in investing activities in Q1 2018 compared to $140 million in Q1 2017. Boston Scientific generated $130 million from financing activities in Q1 2018 compared to $15 million in Q1 2017.
In Q1 2018, Boston Scientific (BSX) generated sales of $2.4 billion compared to $2.2 billion in Q1 2017. The company’s cost of goods sold increased from $650 million in Q1 2017 to $672 million in Q1 2018. The increase was due to the positive impact of cost reductions from Boston Scientific’s process improvement programs and restructuring programs.
Boston Scientific’s (BSX) Cardiovascular segment is comprised of cardiology and peripheral interventions. Its operating income was $290 million, or 31.1% of the segment’s revenues, in Q1 2018, up from $233 million, or 27.3% of the segment’s revenues, in Q1 2017. Worldwide interventional cardiology sales increased 10%, from $590 million in Q1 2017 to $645 million in Q1 2018.
Revenues from Boston Scientific’s (BSX) urology and pelvic health area increased from $262 million in Q1 2017 to $293 million in Q1 2018. Its US revenues increased from $183 million in Q1 2017 to $197 million in Q1 2018.
Worldwide revenues of Boston Scientific’s (BSX) electrophysiology business, which includes less invasive medical technologies for rate and rhythm disorders of the heart, grew 20% from $64 million in Q1 2017 to $75 million in Q1 2018. Electrophysiology revenues from the United States increased from $32 million in Q17 to $35 million in 1Q18.
In January, Boston Scientific (BSX) closed an investment in Millipede and entered into an acquisition option agreement with the company. Millipede is a private company that has developed the IRIS annuloplasty ring system targeted for treating mitral regurgitation.
Of the 24 analysts covering Boston Scientific in June, 19 of them have given the stock a “buy” or higher rating. Five of them have given it a “hold.” The mean rating for the stock is 1.67 with a target price of $32.76. In June, 16 of the 20 analysts covering Abbott Laboratories (ABT) gave the stock a “buy” or higher rating.
In April, Boston Scientific (BSX) closed two acquisitions: NxThera and nVision Medical. The NxThera closing was on April 30. NxThera developed the Rezūm System, which is a minimally invasive therapy in a growing category of treatment options for patients with benign prostatic hyperplasia (or BPH). Boston Scientific already had a minority stake in NxThera.
Medical-technology company Stryker Corp. said Wednesday it is not in discussions with Boston Scientific Corp. regarding a potential takeover. On Monday, The Wall Street Journal reported Stryker had made a takeover approach to Boston Scientific, a move that would create a medical-device giant and would be the latest effort to consolidate a corner of the health-care industry that has produced a raft of large deals lately. Stryker said in a filing with the Securities and Exchange Commission on Wednesday it doesn’t typically comment on these matters, but it chose to respond following market speculation about a possible deal for Boston Scientific.
On June 13, Stryker (SYK) said in a regulatory filing that it’s not in discussions with Boston Scientific (BSX) related to its acquisition. The company released the statement following rumors of a potential acquisition offer made by Stryker to Boston Scientific on June 11, as we reported in Boston Scientific Surges on Rumors of Takeover Bid from Stryker.
Medtech player Stryker isn't in discussions to acquire Boston Scientific, Stryker said Wednesday — prodding shares to pop as Boston Scientific stock toppled more than 6%.
Growth at a reasonable price or the GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.
Stryker's shares rose 7 percent to $174 in premarket trading after falling 9 percent in the last two days. Boston Scientific's shares fell 6.8 percent to $31.60. A potential deal between Stryker and Boston Scientific would create a combined company with a market value of more than $110 billion.
Shares of Boston Scientific Corp. tumbled 6.4%, and Stryker Corp.'s stock shot up 6.4%, after Stryker said it was not in talks to buy Boston Scientific, dispelling speculation after The Wall Street Journal reported on Monday that Boston Scientific had been approached by Stryker. In a filing with the Securities and Exchange Commission, Stryker said in a statement: "While it is Stryker Corporation's (Stryker) longstanding practice not to comment on these matters, today Stryker issued the following statement in response to the market speculation about a proposal to acquire Boston Scientific Corporation: 'Stryker is not in discussions with Boston Scientific Corporation regarding a potential acquisition.'" The medical technology products company's stock had plunged 9.2% in two days since the WSJ report, while Boston Scientific shares had rallied 5.9% and the S&P 500 had inched up 0.3%.
Stryker Corp. said it isn’t in talks with medical-device giant Boston Scientific Corp. about a potential acquisition, responding to a report that it had sought a deal. The Wall Street Journal reported two days ago that Stryker had approached Boston Scientific about a potential merger, sending the target company’s shares soaring. “Stryker is not in discussions with Boston Scientific Corporation regarding a potential acquisition,” the Kalamazoo, Michigan-based company said in a regulatory filing Wednesday.